Equibles does not estimate personal net worth.
Get an email with a short summary when Charles River Laboratories International, Inc. publishes a filing, an earnings call transcript or a press release.
Get CRL alertsGlenn Coleman is recorded as CFO at Charles River Laboratories International, Inc. (CRL). Earlier roles on record: CFO at DENTSPLY SIRONA Inc. (XRAY) until November 7, 2024 and COO at Integra Lifesciences Holdings Corp (IART) until September 23, 2022. Charles River Laboratories International, Inc. reported in an 8-K filed February 18, 2026 that Glenn Coleman was appointed Corporate Executive Vice President and Chief Financial Officer, effective April 6, 2026. Integra Lifesciences Holdings Corp reported in an 8-K filed August 29, 2022 that Glenn Coleman was terminated as Chief Operating Officer, effective October 3, 2022. The proxy statement of DENTSPLY SIRONA Inc. reports total compensation of $3,135,099 for Glenn Coleman in fiscal 2024, including a base salary of $568,075. Disclosed compensation is on record for 8 fiscal years. Glenn Coleman has spoken on 20 earnings calls and 1 other investor event across 3 companies, most recently for Charles River Laboratories International, Inc. on September 14, 2026. Those appearances were for Integra Lifesciences Holdings Corp (IART), DENTSPLY SIRONA Inc. (XRAY) and Charles River Laboratories International, Inc. (CRL). Charles River Laboratories International, Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Other companies whose calls Glenn Coleman spoke on are classified in the Healthcare sector. Other leadership on record at Charles River Laboratories International, Inc. includes Abraham Ceesay (CEO and Board Member), Craig B. Thompson (CEO and Board Member), James C. Foster (CEO and Board Member) and 7 others.
“On February 18, 2026, the Company announced the appointment of Glenn Coleman as its Corporate Executive Vice President and Chief Financial Officer.”
“Glenn Coleman, the Company's current Chief Operating Officer, will cease employment with the Company on that date.”
“So I've been with Charles River now for about five months as Chief Financial Officer.”
“As a reminder, my comments on financial performance will largely be related to non-GAAP results, which exclude amortization and other acquisition and divestiture-related adjustments, costs related primarily to restructuring and efficiency initiatives, and certain other items.”
“I'm pleased to be joining the Charles River team as Chief Financial Officer. I was drawn to the company because of its mission-driven culture and its position as a leader in the life sciences industry.”
“I want to start by expressing what a privilege it's been to be part of the DENTSPLY SIRONA team. I'm proud of what we've accomplished together and remain confident in the strategy and vision that's driving the company's transformation journey.”
“Today, I’ll provide more detail on our second quarter results and an update on our full year 2024 outlook. Let’s begin on Slide 4. Our second quarter revenue was $984 million, representing a decline of 4.2% versus the prior year quarter.”
Start not stated–2024-11-07
Start not stated–2022-09-23
Diagnostics & Research · Healthcare
CFO
XRAY
Medical Instruments & Supplies · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | DENTSPLY SIRONA Inc. (XRAY) | CFO | $568,075 | $3,135,099 |
| 2023 | DENTSPLY SIRONA Inc. (XRAY) | CFO | $644,178 | $3,896,304 |
| 2022 | DENTSPLY SIRONA Inc. (XRAY) | CFO | $166,096 | $4,220,833 |
| 2022 | Integra Lifesciences Holdings Corp (IART) | Former Executive Vice President and Chief Operating Officer | $463,500 | $4,425,564 |
| 2021 | Integra Lifesciences Holdings Corp (IART) | Former Executive Vice President and Chief Operating Officer | $613,292 | $3,537,468 |
| 2020 | Integra Lifesciences Holdings Corp (IART) | Former Executive Vice President and Chief Operating Officer | $559,615 | $2,827,990 |
| 2019 | Integra Lifesciences Holdings Corp (IART) | Executive Vice President and Chief Operating Officer | $585,426 | $3,120,418 |
| 2018 | Integra Lifesciences Holdings Corp (IART) | Executive Vice President and Chief Operating Officer | $556,200 | $2,294,670 |
| 2017 | Integra Lifesciences Holdings Corp (IART) | Executive Vice President and Chief Operating Officer | $536,250 | $2,287,222 |
